Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
This product will be manufactured at Lupin’s Nagpur facility in India
Subscribe To Our Newsletter & Stay Updated